Most recently, Wang et al., in a real-world cohort relying on electronic records, compared GLP1 agonistic therapy like semaglutide with other non-GLP1 agonist weight loss agents for depression and SI and could not support a relationship of induction of depression and SI for semaglutide [79]. Here, GLP1R is linked to depressive disorder.